Global Consortium, Inc., is adding
a Medical Grade Nutraceutical's
Division
-
The division will be comprised of doctors from different
specialties
-
White label products are
being designed to market to
doctors
-
The first tested products are expected to hit the market by
June
Coconut Creek, FL --
March 14, 2019 -- InvestorsHub NewsWire -- Global Consortium, Inc.,
(OTCPINK:
GCGX) is
expanding
Infused Edibles with a new Nutraceuticals line.
The new line
will consist of
lotions,
balms, ointments, liquids, pills, and powders.
The new division will
be overseen by medical doctors and veterinarians
of
varying specialties, custom
designing infused
formulas
not currently available. These
proprietary
formulas
will be designed as a
holistic
approach
to help
treat a wide range of ailments in humans and animals.
Each new
formula
will be compounded and tested by a lab in California prior to being
made available to the general
public.
Some of the formulas
will made available directly to the public, while others will be
marketed to medical
practices
as "White Labeled" products that can be custom tailored to
each doctors
practice.
The first two
specialty
products
are expected to be ready to hit the market by the end of
June.
Global has seen a
steady interest in its "Cannabis Mall Tour" and will be updating
the website with the final terms and conditions shortly. If you
have an interest, you can pre-register at http://www.gcgx.org/tour/
There is a
scheduled
investor conference call for 4:30 PM eastern standard time on
Friday, March 22, 2019.
Global Consortium CEO
Matt Dwyer and other members of the GCGX management team will
provide updates on recent developments and discuss the goals for
the Company in 2019.
In addition,
interested parties have the opportunity to submit questions
concerning the Company prior to the call to Stuart Smith at
SmallCapVoice.Com, Inc. via
email: ssmith@smallcapvoice.com
by 12:00
PM eastern standard time on Monday March 18th,
2019.
Mr. Smith
will compile a list of questions and submit them to the Company
prior to the conference call.
Which
questions will be addressed will be based on the relevance to the
shareholder base, and the question's appropriateness in light of
public disclosure rules.
To access the
call:
Dial-In Number:
1-857-232-0157
Access
Code: 422095
For those unable to
participate in the conference call at that time, a replay will be
available at https://www.smallcapvoice.com/gcgx/
shortly
after the call has concluded.
About Us:
Global Consortium,
Inc., is building America's First Cannabis Mall,
which when completed will house Manufacturing, Distribution,
Delivery, Retail, Testing, and Cultivation all
under one 64,000 square foot building. The Mall will house the
largest Manufacturing facility of THC and CBD Distillate and
Edibles believed to be operational in the United States.
Global Consortium,
Inc., in compliance with SEC regulations, may in the future use
social media outlets like Facebook or Twitter and its own website
to announce key information in compliance with Reg. FD.
Forward-Looking
Statements
This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the United States Securities Act of 1933, as
amended and Section 21(e) of the Securities Exchange Act of 1934,
as amended. Statements in this press release which are not purely
historical are forward-looking statements and include any
statements regarding beliefs, plans, expectations or intentions
regarding the future. Such forward-looking statements include,
among other things, estimates
of services and equipment markets, the release of corporate apps,
growth of the platform, target markets, product releases, product
demand and, business strategy. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among
others, the inherent uncertainties associated with new projects and
development stage companies. These forward-looking statements are
made as of the date of this news release, and we assume no
obligation to update the forward-looking statements or to update
the reasons why actual results could differ from those projected in
the forward-looking statements. Although we believe that any
beliefs, plans, expectations and intentions contained in this press
release are reasonable, there can be no assurance that any such
beliefs, plans, expectations or intentions will prove to be
accurate. Investors should consult all of the information set forth
herein and should also consider that any investment in securities
is at risk.
Details
of the Company's business, finances,
appointments,
and
agreements can be found as part of the Company's continuous public
disclosure on otcmarkets.com.
For additional
information about this release please contact:
Investor
Relations:
www.GCGX.ORG
info@GCGX.ORG
investor@gcgx.com
Twitter:
@Global_GCGXOTC
512-267-2430